An outbreak of fatal lung injuries occurred in Korea between early 2000 and 2011, characterized by rapidly progressing respiratory failure with lung fibrosis, extensive air leak syndrome in many cases, a lack of responsiveness to any treatment, and high mortality rate.[@B1],[@B2],[@B3],[@B4],[@B5] This fatal interstitial lung disease (ILD) was distinct from previously identified ILDs in terms of clinical course as well as radiologic and pathologic findings; therefore, it was considered to be idiopathic.[@B1],[@B2] Toxic chemicals, including polyhexamethylene guanidine (PHMG), in humidifier disinfectants (HDs) were subsequently identified as the cause.[@B1],[@B2] The unique features of this fatal lung disease raised questions regarding the distinct mechanisms underlying the disorder.[@B6] However, there has been no report on the mechanisms underlying HD-associated lung injuries (HDLI) in humans. As altered DNA methylation is associated with development of idiopathic pulmonary fibrosis,[@B6],[@B7] we investigated whether DNA methylation plays a role in HDLI using human samples.

Blood samples from 10 children with HDLI and 10 healthy control children with no exposure to HDs were used to analyze methylation profiles. Clinical characteristics of the study population are summarized in [Table 1](#T1){ref-type="table"}. The mean age at diagnosis of HDLI was 35.4 months (range, 12--81 months) and blood samples for methylation analysis were obtained at a mean age of 11.4 years (range, 7--15 years). Male-to-female rate was 7:3. None of the children in sex-matched control group had any respiratory diseases and their mean age was 7 years. DNA extracted from the peripheral blood mononuclear cells of each subject was analyzed using Infinium Human MethylationEPIC BeadChip (Illumina, San Diego, CA, USA). For quality check (QC) of the methylation data, beta-mixture quantile normalization, and Pearson\'s correlation (range: −1≤r≤1) for reproducibility between samples were performed. For QC of the transcriptome data, all data were normalized with the robust multi-average method implemented in in Affymetrix® Power Tools (Thermo Fisher Scientific, Waltham, MA, USA). Statistical significance for differentially methylated CpG sites was set at \|Δβ\|\>0.2 and *p*\<0.05 using a t-test. Ingenuity® Pathway Analysis (IPA, Ingenuity Systems, Redwood City, CA, USA) was used to represent the functional networks of genes containing differentially methylated CpG sites. Transcriptome analysis was performed using lung tissues from five pediatric patients with HDLI and five control children. Lung tissue was obtained from children with no abnormal lung lesions from Bio-Resource Center at Asan Medical Center to form a control group. The Institutional Review Board of Asan Medical Center reviewed and approved the study protocol (IRB No. 2016-0885).

A total of 171 CpG loci (79 hypermethylated, 92 hypomethylated) showed significantly differential methylation patterns in children with HDLI compared to the controls ([Fig. 1A](#F1){ref-type="fig"}), with a distinctive clustering observed between the two groups ([Fig. 1B](#F1){ref-type="fig"}) ([Table 2](#T2){ref-type="table"}). The top 25 hypomethylated and 25 hypermethylated CpG loci are listed in [Table 2](#T2){ref-type="table"}. SYT8 cg09575189 showed the highest hypomethylation level (\|Δβ\|=0.433, *p*=0.003), whereas cg26786615 (chr16: 86593603) had the highest hypermethylation level (\|Δβ\|=0.519, *p*=0.0006). However, there are a few functional studies of these two genes and no reports in existing literature that provide any clues to the associations between them and fibrosis and/or lung diseases. Potential upstream and downstream regulators of NOTCH1 based on IPA network analysis and its signaling (<https://www.rndsystems.com/pathwyas/notch-signaling-pathway>) are described in [Table 3](#T3){ref-type="table"}.

*NOTCH1* cg14065526 showed a significant degree of hypomethylation (\|Δβ\|=0.304, *p*=0.016). In further network analysis of the genes containing differently methylated CpG sites, "cancer, organismal injury and abnormalities, reproductive system disease (score=41)" was identified as the top network for HDLI, indicating *NOTCH1* as a hub gene ([Fig. 1C](#F1){ref-type="fig"}). The cg14065526 (chr9: 139406352) of *NOTCH1* showed a significantly hypomethylated level (\|Δβ\|=0.304, *p*=0.016). *NOTCH1* transcripts from lung tissues were significantly elevated in HDLI cases compared to unexposed controls (*p*=0.05, each group n=5) ([Fig. 1D](#F1){ref-type="fig"}).

Our present findings from methylation and transcriptome analysis of human blood and lung tissues have identified that *NOTCH1* is involved in the pathogenesis of HDLI. This is the first study to investigate DNA methylation changes and network analyses combined with transcriptomics in pediatric patients with HDLI, which may partially explain the underlying mechanisms of HDLI.

Although *NOTCH1* may be common to the mechanisms of other types of ILDs,[@B8] the results of our current analysis suggest that it also plays a central role in the mechanism of HDLI. Notch1 is involved in angiogenesis, abnormal remodeling of vessels, and mucus hypersecretion, and thereby is associated with pathogenesis of diverse lung diseases.[@B9] The apoptosis of bronchial epithelial cells following exposure to toxic chemicals affects the clearance of apoptotic debris combined with lung fibrosis.[@B10] The overexpression of *NOTCH1*, which is related to its gene hypomethylation, as shown in this study, promotes the differentiation of myofibroblasts, which is a critical step in pulmonary fibrosis.[@B3] NOTCH1 has been identified to be involved in bleomycin-induced lung diseases and paraquat poisoning, for which the main mechanism is pulmonary fibrosis.[@B11],[@B12] The results of previous reports and our present findings provide strong evidence for the involvement of *NOTCH1* in the pathogenesis of fatal fibrotic lung diseases and give new insights into the possible mechanisms of lung injuries caused by inhalation of unidentified but harmful chemicals that are commonly used.

The inhalation of toxic chemicals damages the epithelial lining in the airway, initiating a series of processes including disruption of epithelial lining, alterations of diverse mediators and chemokine levels, and induction of epithelium-to-mesenchymal transition (EMT).[@B13] NOTCH1 regulates EMT through various signaling factors, such as TGF-β, NF-κB, and β-catenin.[@B10] It has been reported that exposure to PHMG phosphate can induce EMT in a dose-dependent manner.[@B14] A previous study identified that PHMG could induce EMT through the Akt/Notch signaling pathway.[@B15] This prior evidence, in combination with our current data, further supports the notion that *NOTCH1* plays a role in the pathogenesis of HDLI via EMT following exposure to HDs that contain PHMG.

Our study had some limitations, including its small sample size. However, the results of the current study are significant in that HDLI is an exceptional disease, and the acquisition of blood and lung tissue in our patients was not easy. In our present cohort, there were time lags with a mean of 9 years between diagnosis of HDLI and blood sampling. The methylation patterns in the blood obtained after a time lag of 9 years may have been affected by diverse factors.[@B16] A previous study showed that less than 30% of individuals showed methylation changes in epigenome- wide DNA methylation analysis on average 11 years apart, even with intra-individual variations.[@B16] We could not perform methylation analysis in human lung tissues in the current study, as these samples were not available. In spite of the limitations, methylation changes observed in the present study could be helpful to elucidate the mechanisms underlying HDLI with stable disease state.

In conclusion, we have identified *NOTCH1* pathways as one of the possible main fibrogenetic mechanisms of HDLI in children following exposure to PHMG phosphate. Further identification and elucidation of the mechanisms underlying this fatal lung disease are essential for the future development of therapeutics and prevention of lung diseases after exposure to harmful domestic chemicals.

This study was funded by the Korea Ministry of Environment (MOE) as "the Environmental Health Action Program (2016001360006)" and partially supported by the Environmental Health Center for Hazardous Chemical Exposure funded by the Ministry of Environment Republic of Korea (2019).

The authors have no potential conflicts of interest to disclose.

**AUTHOR CONTRIBUTIONS:** **Conceptualization:** Eun Lee, Mi Jin Kang, Jeong-Hyun Kim, and Soo-Jong Hong.**Data curation:** Seung-Hwa Lee, So-Yeon Lee, Hyun-Ju Cho, Jisun Yoon, Sungsu Jung, Yangsoon Park, Dong Kyu Oh, and Sang-Bum Hong.**Formal analysis:** Mi Jin Kang and Jeong-Hyun Kim.**Funding acquisition:** Eun Lee and Soo-Jong Hong.**Investigation:** Eun Lee, Mi Jin Kang, Jeong-Hyun Kim, Dong Kyu Oh, Sang-Bum Hong, and Soo-Jong Hong.**Methodology:** Mi Jin Kang, Jeong-Hyun Kim, Seung-Hwa Lee, and Yangsoon Park.**Project administration:** Eun Lee, Mi Jin Kang, Jeong-Hyun Kim, and Soo-Jong Hong.**Resources:** Eun Lee and Soo-Jong Hong.**Software:** Mi Jin Kang and Jeong-Hyun Kim.**Supervision:** Soo-Jong Hong.**Validation:** Eun Lee, Mi Jin Kang, Jeong-Hyun Kim, Seung-Hwa Lee, and Yangsoon Park.**Writing---original draft:** Eun Lee.**Writing---review & editing:** Eun Lee, Jeong-Hyun Kim, and Soo-Jong Hong.**Approval of final manuscript:** all authors.

![Results of methylation, network, and *NOTCH1* expression analysis in pediatric HDLI cases. (A) Volcano plot of differentially methylated CpG sites. (B) Heatmap of differentially methylated CpG sites between children with humidifier disinfectant associated lung injuries and unexposed healthy controls. Differentially methylated CpG loci indicated by asterisk. (C) The top network of differentially methylated CpG sites was found to be "cancer, organismal injury and abnormalities, reproductive system disease" and was derived from genes containing hyper-/hypo-methylated CpG sites associated with HDLI. (D) The transcriptional expression of *NOTCH1* between HDLI cases and the control group (*p*=0.05, t-test, nonparametric methods were applied, and no correction for multiple testing was done due to the small sample size of each group, n=5 for each group). HDLI, humidifier disinfectant lung injuries.](ymj-61-186-g001){#F1}

###### Clinical Characteristics of the Study Population

![](ymj-61-186-i001)

  Mean±SD or number                  Methylation study from blood samples   Transcriptome study with lung tissues             
  ---------------------------------- -------------------------------------- --------------------------------------- --------- ----------
  Number                             10                                     10                                      5         5
  Age at sample collection (yr)      7.0±0.6                                11.4±3.6                                9.0±2.4   1.8±0.8
  Age at diagnosis of HDLI (month)   NA                                     35.4±1.8                                NA        30.2±9.5
  Sex, male:female                   7:3                                    7:3                                     2:3       2:3
  Dyspnea at diagnosis               0/10                                   9/10                                    0/5       5/5
  Pneumothorax during illness        0/10                                   4/10                                    0/5       5/5
  Oxygen need                        0/10                                   9/10                                    0/5       5/5
  Ventilator care                    0/10                                   2/10                                    0/5       0/5
  Mortality                          0/10                                   0/10                                    0/5       0/5

HDLI, humidifier disinfectant lung injuries; NA, not applicable.

###### Top 25 Hypomethylated and Top 25 Hypermethylated Sites Showing Significantly Different Levels in Pediatric Patients with HDLI Compared to Unexposed Healthy Control Children
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  Methylation type^\*^   Illumina ID   Chr.   CpG coordinate   (Nearest) gene            Position^†^            Beta value (average)   Δβ      *p* value   
  ---------------------- ------------- ------ ---------------- ------------------------- ---------------------- ---------------------- ------- ----------- --------
  Hypo-                  cg09575189    11     1855561          *SYT8*                    TSS200                 0.376                  0.808   -0.433      0.003
  Hypo-                  cg05751055    6      33036504         *HLA-DPA1*                Gene body              0.520                  0.922   -0.402      0.022
  Hypo-                  cg11437465    6      33036958         *HLA-DPA1*                Gene body              0.442                  0.806   -0.364      0.018
  Hypo-                  cg05340866    7      148032668        *CNTNAP2*                 Gene body              0.200                  0.563   -0.363      0.016
  Hypo-                  cg07474670    12     124831017        *NCOR2*                   Gene body              0.357                  0.714   -0.357      0.027
  Hypo-                  cg07791065    6      113786051        *(LINC02518)*                                    0.370                  0.726   -0.356      0.025
  Hypo-                  cg13318082    1      19669688         *CAPZB*                   Gene body              0.616                  0.965   -0.348      0.006
  Hypo-                  cg05526809    4      1309416          *MAEA*                    Gene body              0.508                  0.855   -0.346      0.018
  Hypo-                  cg05554406    7      2834869          *GNA12*                   Gene body              0.419                  0.760   -0.340      0.028
  Hypo-                  cg20976286    15     28054345         *OCA2*                    Gene body              0.405                  0.735   -0.330      0.008
  Hypo-                  cg06378142    19     50119633         *PRR12*                   Gene body              0.409                  0.737   -0.328      0.011
  Hypo-                  cg11074353    6      153066907        *(VIP)*                                          0.488                  0.811   -0.323      0.023
  Hypo-                  cg20981163    6      33049983         *HLA-DPB1*                Gene body              0.369                  0.691   -0.323      0.015
  Hypo-                  cg12858166    6      33033176         *HLA-DPA1*                3′UTR                  0.415                  0.738   -0.322      0.045
  Hypo-                  cg24906015    2      58482767         *(FANCL)*                                        0.540                  0.862   -0.321      0.011
  Hypo-                  cg07846874    7      11568529         *THSD7A*                  Gene body              0.512                  0.830   -0.318      0.048
  Hypo-                  cg17635970    8      133117602        *HHLA1*                   TSS200                 0.548                  0.861   -0.313      0.023
  Hypo-                  cg10978613    8      117473031        *(LINC00536)*                                    0.561                  0.874   -0.313      0.041
  Hypo-                  cg19484093    4      119990940        *(SYNP02)*                                       0.417                  0.727   -0.310      0.016
  Hypo-                  cg16715186    22     45981385         *FBLN1*                   Gene body              0.522                  0.832   -0.309      0.004
  Hypo-                  cg16776298    1      4784556          *AJAP1*                   Gene body              0.499                  0.805   -0.306      0.009
  Hypo-                  cg14065526    9      139406352        *NOTCH1*                  Gene body              0.168                  0.473   -0.304      0.016
  Hypo-                  cg17348244    7      786861           *HEATR2*                  Gene body              0.624                  0.926   -0.303      0.029
  Hypo-                  cg07336544    10     79194347         *KCNMA1*                  Gene body              0.430                  0.717   -0.287      0.019
  Hypo-                  cg04869491    15     33757740         *RYR3; RYR3*              Gene body              0.643                  0.929   -0.286      0.015
  Hyper-                 cg04105547    16     965857           *LMF1*                    Gene body              0.557                  0.254   0.303       0.043
  Hyper-                 cg07093060    3      174092757        *(NAALADL2)*                                     0.751                  0.447   0.304       0.017
  Hyper-                 cg18932722    12     94987650         *TMCC3*                   5′UTR                  0.864                  0.557   0.307       0.022
  Hyper-                 cg06264089    12     10563947         *KLRC4-KLRK1*             TSS1500                0.686                  0.378   0.307       0.002
  Hyper-                 cg04263740    7      65375514         *VKORC1L1*                Gene body              0.737                  0.430   0.308       0.027
  Hyper-                 cg01359658    7      2426868          *(EIF3B)*                                        0.633                  0.321   0.312       0.010
  Hyper-                 cg27114706    12     92527244         *LOC256021*               Gene body              0.778                  0.465   0.312       0.012
  Hyper-                 cg01235375    2      66836203         *LOC100507073*            Gene body              0.804                  0.490   0.315       0.024
  Hyper-                 cg13910001    20     31622082         *BPIFB6*                  Exon                   0.453                  0.135   0.319       0.018
  Hyper-                 cg17155524    4      2305734          *ZFYVE28*                 Gene body              0.747                  0.426   0.321       0.030
  Hyper-                 cg18828306    11     17555864         *USH1C*                   Gene body              0.605                  0.284   0.321       0.041
  Hyper-                 cg05971102    2      3753297          *DCDC2C*                  Gene body              0.616                  0.293   0.323       0.011
  Hyper-                 cg01463139    1      158435277        *OR10K1*                  TSS200                 0.756                  0.429   0.327       0.033
  Hyper-                 cg08880082    14     90165664         *(FOXN3)*                                        0.876                  0.542   0.334       0.036
  Hyper-                 cg15570860    11     8986840          *TMEM9B; TMEM9B-AS1*      TSS1500; body          0.701                  0.368   0.334       0.038
  Hyper-                 cg05961492    22     47459539         *TBC1D22A*                Gene body              0.467                  0.133   0.334       0.006
  Hyper-                 cg14080585    20     60639721         *TAF4*                    Exon                   0.550                  0.208   0.342       0.004
  Hyper-                 cg01886237    4      122378794        *(QRFPR)*                                        0.675                  0.329   0.346       0.022
  Hyper-                 cg04234412    22     24373322         *LOC391322*               Gene body              0.834                  0.481   0.353       0.022
  Hyper-                 cg21193926    14     76443578         *TGFB3*                   Gene body              0.694                  0.331   0.363       0.018
  Hyper-                 cg04531182    12     10563981         *KLRC4-KLRK1*             TSS1500                0.619                  0.256   0.363       0.002
  Hyper-                 cg25099095    6      156954565        *(ARID1B)*                                       0.735                  0.367   0.369       0.045
  Hyper-                 cg08041188    12     10564015         *KLRC4-KLRK1*             TSS1500                0.698                  0.326   0.372       0.002
  Hyper-                 cg11547201    5      80501337         *RASGRF2; RNU5E; RNU5D*   Body; TSS200; TSS200   0.866                  0.477   0.389       0.005
  Hyper-                 cg26786615    16     86593603         *(MTHFSD)*                                       0.779                  0.261   0.519       0.0006

HDLI, humidifier disinfectant lung injuries; TSS, transcription start site; UTR, untranslated region.

^\*^Hyper- and hypo- indicate the methylation levels of patients compared to controls, ^†^TSS200 and TSS1500 indicate the distance within 200 bp and 1500 bp from TSS, respectively.

###### Gene Expression of Potential Upstream and Downstream Regulators of NOTCH1 in Formalin-Fixed, Paraffin-Embedded Lung Tissue Specimens from Children with HDLI and the Control Group
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  Category                 Gene       mRNA accession   Fold change   *p* value
  ------------------------ ---------- ---------------- ------------- -----------
  Upstream regulators                                                
                           *DAP3*     NM_001199849     1.41          0.017
                           *ACTN1*    NM_001102        1.56          0.003
                           *ACTN2*    NM_001103        -1.23         0.213
                           *ACTN3*    NM_001104        -1.02         0.812
                           *ACTN4*    NM_004924        1.07          0.590
                           *LONP1*    NM_001276479     -1.17         0.235
                           *ALKBH1*   NM_006020        -1.27         0.046
  Downstream regulators                                              
   Canonical pathway       *HES1*     NM_005524        -1.12         0.119
                           *HEY1*     NM_001040708     1.09          0.317
                           *MYC*      NM_002467        -1.02         0.841
                           *BCL2*     NM_000633        1.24          0.024
                           *CCND1*    NM_053056        1.38          0.031
   Non-canonical pathway   *CHUK*     NM_001278        1.25          0.138
                           *NFKB1*    NM_001165412     1.18          0.124
                           *PIK3CA*   NM_006218        1.11          0.457
                           *AKT1*     NM_001014431     1.12          0.338
                           *AKT2*     NM_001243027     1.07          0.107
                           *AKT3*     NM_001206729     -1.02         0.884
                           *CTNNB1*   NM_001098209     1.10          0.570
   Lysosomal degradation   *NUMB*     NM_001005743     1.11          0.406

HDLI, humidifier disinfectant lung injuries.

Upstream regulators are predicted using Ingenuity Pathway Analysis. Downstream regulators of *NOTCH1* are notified from (<https://www.rndsystems.com/pathways/notch-signaling-pathway>). Formalin-Fixed Paraffin-Embedded lung tissue specimens from HDLI cases (n=5) and controls (n=5).
